Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

被引：2
|
作者：
Hoadley, Katherine A. [1 ]
Powell, Bradford C. [1 ]
Kanavy, Dona [1 ]
Marron, David [1 ]
Mose, Lisle E. [1 ]
Hyslop, Terry [2 ]
Berry, Donald A. [3 ]
Hahn, Olwen [4 ]
Tolaney, Sara M. [5 ]
Sikov, William M. [6 ]
Perou, Charles M. [1 ]
Carey, Lisa A. [1 ]
机构：
[1] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[2] Duke Univ, Durham, NC USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Dana Farber Partners CancerCare, Boston, MA USA
[6] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P4-05-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-05-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
    Hoadley, K. A.
    Hyslop, T.
    Fan, C.
    Berry, D. A.
    Hahn, O.
    Tolaney, S. M.
    Sikov, W. M.
    Perou, C. M.
    Carey, L. A.
    CANCER RESEARCH, 2017, 77
  • [2] Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets
    Brooke M. Felsheim
    Aranzazu Fernandez-Martinez
    Cheng Fan
    Adam D. Pfefferle
    Michele C. Hayward
    Katherine A. Hoadley
    Naim U. Rashid
    Sara M. Tolaney
    George Somlo
    Lisa A. Carey
    William M. Sikov
    Charles M. Perou
    npj Breast Cancer, 11 (1)
  • [3] CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
    Sikov, William M.
    Polley, Mei-Yin
    Twohy, Erin
    Perou, Charles M.
    Singh, Baljit
    Berry, Donald A.
    Tolaney, Sara M.
    Somlo, George
    Port, Elisa R.
    Ma, Cynthia X.
    Kuzma, Charles S.
    Mamounas, Eleftherios P.
    Golshan, Mehra
    Bellon, Jennifer Ruth
    Collyar, Deborah E.
    Hahn, Olwen Mary
    Hudis, Clifford A.
    Winer, Eric P.
    Partridge, Ann H.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).
    Golshan, Mehra
    Cirrincione, Constance T.
    Carey, Lisa A.
    Sikov, William M.
    Berry, Donald A.
    Burstein, Harold J.
    Overmoyer, Beth
    Henry, Norah Lynn
    Somlo, George
    Port, Elisa R.
    Winer, Eric P.
    Hudis, Clifford A.
    Ollila, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Triple-negative breast cancer (TNBC) phosphoproteomics
    Gaitero, Sara Fernandez
    Zagorac, Ivana
    Lopez-Acosta, Jose Francisco
    Gomez-Lopez, Gonzalo
    Pisano, David Gonzalez
    Peralta, Javier Munoz
    Manso, Luis
    Alonso, Soledad
    Penning, Renske
    Altelaar, Maarten
    Heck, Albert J. R.
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2017, 77
  • [6] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
  • [7] Neoadjuvant treatments for triple-negative breast cancer (TNBC)
    von Minckwitz, G.
    Martin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 39
  • [8] Phosphoproteomic portraits of triple-negative breast cancer (TNBC)
    Quintela-Fandino, Miguel
    Zagorac, Ivana
    Lopez-Acosta, Jose Francisco
    Gomez, Gonzalo
    Pisano, David G.
    Munoz, Javier
    Manso, Luis
    Alonso, Soledad
    Penning, Renske
    Altelaar, Maarten
    Heck, Albert J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Lipogenesis inhibition in triple-negative breast cancer (TNBC)
    Giro-Perafita, Ariadna
    Palomeras, Sonia
    Polonio, Emma
    Ciurana, Joaquim
    Vinas, Gemma
    Puig, Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S58 - S58
  • [10] CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
    Shepherd, Jonathan H.
    Ballman, Karla
    Polley, Mei-Yin C.
    Campbell, Jordan D.
    Fan, Cheng
    Selitsky, Sara
    Fernandez-Martinez, Aranzazu
    Parker, Joel S.
    Hoadley, Katherine A.
    Hu, Zhiyuan
    Li, Yan
    Soloway, Matthew G.
    Spears, Patricia A.
    Singh, Baljit
    Tolaney, Sara M.
    Somlo, George
    Port, Elisa R.
    Ma, Cynthia
    Kuzma, Charles
    Mamounas, Eleftherios
    Golshan, Mehra
    Bellon, Jennifer R.
    Collyar, Deborah
    Hahn, Olwen M.
    Hudis, Clifford A.
    Winer, Eric P.
    Partridge, Ann
    Hyslop, Terry
    Carey, Lisa A.
    Perou, Charles M.
    Sikov, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1323 - +
12345